TRCT
DXCM icon

Tower Research Capital (TRC)’s DexCom DXCM Stock Holding History

Tower Research Capital (TRC)’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.04M Buy
32,556
+2,167
+7% +$151K 0.05% 334
2025
Q4 		$2.02M Buy
30,389
+21,143
+229% +$1.37M 0.05% 327
2025
Q3 		$622K Buy
9,246
+1,502
+19% +$119K 0.02% 725
2025
Q2 		$676K Sell
7,744
-633
-8% -$49.6K 0.02% 755
2025
Q1 		$572K Sell
8,377
-27,673
-77% -$2.26M 0.02% 761
2024
Q4 		$2.8M Sell
36,050
-349
-1% -$25.8K 0.06% 280
2024
Q3 		$2.44M Sell
36,399
-14,992
-29% -$1.23M 0.06% 220
2024
Q2 		$5.83M Buy
51,391
+19,366
+60% +$2.45M 0.1% 170
2024
Q1 		$4.44M Sell
32,025
-30,675
-49% -$3.86M 0.11% 133
2023
Q4 		$7.78M Buy
62,700
+5,256
+9% +$537K 0.1% 168
2023
Q3 		$5.36M Buy
57,444
+49,052
+585% +$5.53M 0.17% 99
2023
Q2 		$1.08M Buy
8,392
+640
+8% +$77.4K 0.04% 470
2023
Q1 		$900K Sell
7,752
-7,282
-48% -$815K 0.03% 509
2022
Q4 		$1.7M Sell
15,034
-78,814
-84% -$8.65M 0.07% 203
2022
Q3 		$7.56M Buy
93,848
+43,590
+87% +$3.69M 0.12% 139
2022
Q2 		$3.75M Sell
50,258
-55,274
-52% -$5.04M 0.08% 197
2022
Q1 		$13.5M Buy
105,532
+65,956
+167% +$7.21M 0.13% 137
2021
Q4 		$5.31M Buy
39,576
+15,964
+68% +$2.29M 0.09% 179
2021
Q3 		$3.23M Buy
23,612
+10,336
+78% +$1.3M 0.08% 170
2021
Q2 		$1.42M Sell
13,276
-37,200
-74% -$3.57M 0.04% 449
2021
Q1 		$4.54M Buy
50,476
+43,136
+588% +$4.05M 0.08% 231
2020
Q4 		$678K Sell
7,340
-12,152
-62% -$1.09M 0.02% 771
2020
Q3 		$2.01M Buy
19,492
+11,504
+144% +$1.2M 0.02% 386
2020
Q2 		$810K Buy
7,988
+7,776
+3,668% +$696K 0.03% 662
2020
Q1 		$14K Buy
+212
New +$13.2K ﹤0.01% 1870
2019
Q4 		– Sell
-5,500
Closed -$205K – 3722
2019
Q3 		$205K Buy
+5,500
New +$214K 0.01% 980
2019
Q2 		– Sell
-8,472
Closed -$252K – 3818
2019
Q1 		$252K Buy
+8,472
New +$298K 0.02% 1032
2018
Q4 		– Sell
-15,036
Closed -$538K – 3913
2018
Q3 		$538K Buy
15,036
+9,076
+152% +$281K 0.04% 441
2018
Q2 		$142K Sell
5,960
-1,180
-17% -$25K 0.01% 1223
2018
Q1 		$132K Buy
+7,140
New +$106K 0.01% 1090
2017
Q3 		– Sell
-21,240
Closed -$388K – 3842
2017
Q2 		$388K Buy
21,240
+15,956
+302% +$295K 0.04% 244
2017
Q1 		$112K Sell
5,284
-3,684
-41% -$71.9K 0.01% 428
2016
Q4 		$134K Buy
+8,968
New +$159K 0.01% 828
2016
Q2 		– Sell
-724
Closed -$12K – 4523
2016
Q1 		$12K Buy
+724
New +$12.1K ﹤0.01% 1756
2015
Q4 		– Sell
-796
Closed -$17K – 4586
2015
Q3 		$17K Sell
796
-3,684
-82% -$82.2K ﹤0.01% 1872
2015
Q2 		$90K Sell
4,480
-1,080
-19% -$19K 0.01% 927
2015
Q1 		$87K Buy
5,560
+1,484
+36% +$22.4K 0.01% 1005
2014
Q4 		$56K Sell
4,076
-228
-5% -$2.79K 0.01% 964
2014
Q3 		$43K Sell
4,304
-22,344
-84% -$228K ﹤0.01% 1657
2014
Q2 		$264K Buy
26,648
+26,348
+8,783% +$233K 0.03% 485
2014
Q1 		$3K Sell
300
-188
-39% -$1.94K ﹤0.01% 3606
2013
Q4 		$4K Sell
488
-25,804
-98% -$204K ﹤0.01% 3665
2013
Q3 		$186K Buy
26,292
+7,700
+41% +$48.8K 0.02% 798
2013
Q2 		$104K Buy
+18,592
New +$89.1K 0.01% 486

Other funds holding DXCM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Tower Research Capital (TRC)'s DXCM Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its DexCom (DXCM) stake by 7.1% in Q1 2026, buying an estimated $151K and bringing the position to 32,556 shares worth $2.04M. The position accounts for 0.05% of the portfolio, ranked #334.

Tower Research Capital (TRC) first reported a position in DXCM in Q2 2013 and has held it in 44 quarters since. The position peaked at $13.5M in Q1 2022. 957 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Tower Research Capital (TRC) held 32,556 shares of DexCom worth $2.04M as of Q1 2026.
  • Tower Research Capital (TRC) bought 2,167 DexCom shares in Q1 2026, an estimated $151K.
  • DexCom made up 0.05% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #334 holding.
  • Tower Research Capital (TRC) first reported a position in DexCom in Q2 2013 and has held it in 44 quarters since.
  • Tower Research Capital (TRC)'s DexCom position peaked at $13.5M in Q1 2022.
  • 957 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.